Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET

Journal of Nuclear Medicine

Volumn 46, Issue 10, 2005, Pages 1625-1632

  Drzezga, Alexander ^a,f   Grimmer, Timo ^a   Riemenschneider, Matthias ^a   Lautenschlager, Nicola ^b   Siebner, Hartwig ^c,d   Alexopoulus, Panagiotis ^a   Minoshima, Satoshi ^e   Schwaiger, Markus ^a   Kurz, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF KIEL   (Germany)

^d Center of Psychosocial Medicine   (Germany)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's disease; APOE genotype; Mild cognitive impairment; PET; Predictive value

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FOLLOW UP; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOTYPE; GLUCOSE METABOLISM; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MALE; METHODOLOGY; PHENOTYPE; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 33644697324     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Petersen RC. Mild cognitive impairment, and early Alzheimer's disease. Neurologist. 1995;1:326-344.
2. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr. 2004;16:129-140.
3. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997;278:1363-1371.
4. Small GW. Differential diagnosis and early detection of dementia. Am J Geriatr Psychiatry. 1998;6:S26-S33.
5. Friedrich MJ. Mild cognitive impairment raises Alzheimer disease risk. JAMA. 1999;282:621-622.
6. Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med. 1994;35:391-398.
7. Mazziotta JC, Frackowiak RS, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med. 1992;22:233-246.
8. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord. 1995;9:6-16.
9. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94.
10. Nordberg A. Application of PET in dementia disorders. Acta. Neurol Scand Suppl. 1996;168:71-76.
11. Small GW, Leiter F. Neuroimaging for diagnosis of dementia. J Clin Psychiatry. 1998;59(suppl 11):4-7.
12. 18F]fluoro-2-deoxy-D-glucose/ positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA. 2001;98:10966-10971.
13. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003;60:1374-1377.
14. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104-1113.
15. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59-66.
16. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332-2340.
17. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12:851-855.
18. Ashford JW. APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci. 2004;23:157-165.
19. Small GW, Komo S, La Rue A, et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci 1996;802:70-78.
20. Tsuang D, Larson EB, Bowen J, et al. The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series. Arch Neurol. 1999;56:1489-1495.
21. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
23. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159-1165.
24. Roman GC, Tatemichi TK, Erkinjunti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
25. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994;44:609-614.
26. Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part IV. Rating of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993;43:2457-2465.
27. Welsh K, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol. 1991;48:278-281.
28. Thalmann B, Monsch AU, Schreittner M, et al. The CERAD neuropsychological assessment battery (CERAD-NAB): a minimal data set as a common tool for German-speaking Europe [abstract]. Neurobiol Aging. 2000;21:30.
29. Gauggel S, Schmidt A. How useful is the German version of the geriatric depression scale GDS [in German]? Geriatr Praxis. 1995;6:33-36.
30. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatry. 1983;17:37-49.
31. Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem. 1997;43:1657-1659.
32. Mielke R, Zerres K, Uhlhaas S, Kessler J, Heiss WD. Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease. Neurosci Lett. 1998;254:49-52.
33. Drzezga A, Riemenschneider M, Strassner B, et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology. 2005;64:102-107.
34. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.
35. Bartenstein P, Minoshima S, Hirsch C, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med. 1997;38:1095-1101.
36. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med. 1999;40:737-746.
37. 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med. 2001;42:548-557.
38. Talairach J, Tournoux, P. Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System-An Approach to Cerebral Imaging. New York, NY: Thieme Medical Publishers; 1988.
39. Teipel SJ, Willoch E, Ishii K, et al. Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease. Neurobiol Aging. May 20, 2005 [Epub ahead of print].
40. McKhann G, Folstein M, Katzmann R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
41. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
42. Chang CY, Silverman DH. Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease. Expert Rev Mol Diagn. 2004;4:63-69.
43. Herholz K. PET studies in dementia. Ann Nucl Med. 2003;17:79-89.
44. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115-121.
45. Bottino CM, Almeida OP. Can neuroimaging techniques identify individuals at risk of developing Alzheimer's disease? Int Psychogeriatr. 1997;9:389-403.